转移性结直肠癌患者的分子图谱与治疗选择
Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.
作者信息
Miyamoto Yuji, Zhang Wu, Lenz Heinz-Josef
机构信息
Division of Medical Oncology, Norris Comprehensive Cancer Center, Shanon A. Carpenter Laboratory, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033 USA.
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
出版信息
Indian J Surg Oncol. 2017 Dec;8(4):580-590. doi: 10.1007/s13193-016-0543-z. Epub 2016 Jul 27.
Over the last 20 years, median survival for patients with metastatic colorectal cancer (CRC) has remarkably improved from about 12 to over 30 months, mainly because of the development of new agents and patient selection using predictive biomarkers. However, the identification of the most effective treatment for an individual patient is still a challenge. Molecular profiling of CRC has made great progress, but it is limited by tumor heterogeneity and absence of driver mutation. However, RAS, BRAF, and microsatellite instability are validated biomarker recommended by NCCN and ESMO. In this review, we discuss recent advances and future developments.
在过去20年中，转移性结直肠癌（CRC）患者的中位生存期已从约12个月显著提高到超过30个月，这主要归功于新药物的研发以及利用预测性生物标志物进行的患者选择。然而，为个体患者确定最有效的治疗方法仍然是一项挑战。结直肠癌的分子谱分析取得了很大进展，但受到肿瘤异质性和驱动突变缺失的限制。不过，RAS、BRAF和微卫星不稳定性是美国国立综合癌症网络（NCCN）和欧洲医学肿瘤学会（ESMO）推荐的经过验证的生物标志物。在本综述中，我们讨论了近期的进展和未来的发展。
Zotero 插件